Scripps Clinic and Research Foundation

The Scripps Research Institute

Rorer Biotechnology Inc.

Carol A Fulcher

Theodore S Zimmerman

Paul A Foster

William N Drohan

Dorothea H Scandella

Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.

Factor VIII coagulant polypeptides and monoclonal antibodies to them

Peptides which inhibit the binding of yon Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.

Factor VIII binding domain of von Willebrand factor

Fragments of Factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Factor VIII coagulant polypeptides: method of making

Peptides which inhibit the binding of von Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.

Factor VIII binding domain of von Willebrand Factor

Fragments of the factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Factor VIII coagulant polypeptides

New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.

Recombinant Factor VIIIC fragments

Protein fragments containing Factor VIII binding domain of von

Recombinant factor VIIIC derived fragments

Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.

Factor VIII coagulant polypeptides and monoclonal antibodies tof them

The present invention is a protein purification column comprising an organic substrate matrix having low reactivity to proteins, said matrix being capable of maintaining monoclonal antibodies attached thereto in an external configuration and preventing interaction with the protein to be bound to the antibody, and a monoclonal antibody attached to the substrate, the monoclonal antibody having a specific affinity for the protein to be isolated. The present invention also is a method for isolating and purifying specific protein from a solution, wherein

Flouroplastic immunoaffinity columns for purification of blood proteins

Fragments of human Factor VIII:C which bind to antibody inhibitors of Factor VIII in patients afflicted with such inhibitors are disclosed. The method of treating Factor VIII inhibitors, by administering one or more of these fragments, is also disclosed.

Growing community of inventors

La Jolla, CA, United States of America

Carol A Fulcher